These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28378877)

  • 21. Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.
    Povsic TJ; Scott R; Mahaffey KW; Blaustein R; Edelberg JM; Lefkowitz MP; Solomon SD; Fox JC; Healy KE; Khakoo AY; Losordo DW; Malik FI; Monia BP; Montgomery RL; Riesmeyer J; Schwartz GG; Zelenkofske SL; Wu JC; Wasserman SM; Roe MT
    Cardiovasc Drugs Ther; 2017 Aug; 31(4):445-458. PubMed ID: 28735360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacological need and pharmacological economy in cardiology].
    Garattini S
    G Ital Cardiol; 1997 Dec; 27(12):1315-8. PubMed ID: 9470067
    [No Abstract]   [Full Text] [Related]  

  • 23. The importance of drug discovery for treatment of cardiovascular diseases.
    Kennedy C
    Future Med Chem; 2013 Mar; 5(4):355-7. PubMed ID: 23495678
    [No Abstract]   [Full Text] [Related]  

  • 24. Design of innovative therapeutics for pharmacoresistant epilepsy: challenges and needs.
    Weaver DF
    Epilepsia; 2013 May; 54 Suppl 2():56-9. PubMed ID: 23646972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discontinued drugs in 2012: cardiovascular drugs.
    Zhao HP; Jiang HM; Xiang BR
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1437-51. PubMed ID: 23992034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Commentary on R&D Trends Away from General Medicine/Cardiovascular Drugs: Can the FDA Help Reverse the Trend?
    Meyer RJ
    Clin Pharmacol Ther; 2017 Aug; 102(2):186-188. PubMed ID: 28636269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Affairs of the Heart: Innovation in Cardiovascular Research and Development.
    Honig P; Terzic A
    Clin Pharmacol Ther; 2017 Aug; 102(2):162-168. PubMed ID: 28718903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care.
    Stewart A; Schmier JK; Luce BR
    Am Heart J; 1999 May; 137(5):S53-61. PubMed ID: 10220598
    [No Abstract]   [Full Text] [Related]  

  • 29. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials.
    Hlatky MA
    Am Heart J; 1999 May; 137(5):S41-6. PubMed ID: 10220595
    [No Abstract]   [Full Text] [Related]  

  • 30. [Underutilization of cardiovascular pharmacotherapy: how to pay for it?].
    Wehling M
    Dtsch Med Wochenschr; 2004 Feb; 129(7):330. PubMed ID: 14765334
    [No Abstract]   [Full Text] [Related]  

  • 31. Reference-based pricing of prescription drugs.
    McLaughlin PR
    Can J Cardiol; 1997 Jan; 13(1):31-2. PubMed ID: 9039062
    [No Abstract]   [Full Text] [Related]  

  • 32. MSD spring retreat.
    Tildon-Burton JE
    Del Med J; 2006 Apr; 78(4):133-4. PubMed ID: 16719141
    [No Abstract]   [Full Text] [Related]  

  • 33. A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada. Canadian Cardiovascular Society.
    Can J Cardiol; 1997 Jan; 13(1):33-45. PubMed ID: 9039063
    [No Abstract]   [Full Text] [Related]  

  • 34. The preventive polypill--much promise, insufficient evidence.
    Reddy KS
    N Engl J Med; 2007 Jan; 356(3):212. PubMed ID: 17229947
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiovascular and Hematological Medicine in 2019 - Advances and Insights.
    Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2019; 17(1):2. PubMed ID: 31556359
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug discovery in the next decade: innovation needed ASAP.
    Bennani YL
    Drug Discov Today; 2011 Sep; 16(17-18):779-92. PubMed ID: 21704185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro diagnostics in the development and use of cardiovascular medicines.
    Leadley RJ
    Curr Opin Mol Ther; 2010 Dec; 12(6):639-46. PubMed ID: 21154155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Canadian Cardiovascular Society and reference-based drug pricing.
    Olley PM; McLaughlin PR
    Can J Cardiol; 1998 May; 14(5):669-70. PubMed ID: 9627521
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug treatment and cost of cardiovascular disease in Australia.
    Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
    Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxins and drug discovery.
    Harvey AL
    Toxicon; 2014 Dec; 92():193-200. PubMed ID: 25448391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.